Travere achieved record quarterly revenue of $220.2 million, driven by Filspari's expansion into FSGS, though management faces a CEO transition and increased competition in the IgA nephropathy market.
Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
Travere Therapeutics CEO Eric M. Dube Sells $13.1M of Stock
Eric M. Dube, CEO, sold 243,735 shares of Travere Therapeutics, Inc. at $52.97 to $55.02 a share (average $53.82) in 3 transactions, worth $13.1M in total on Oct 15, 2026. Shares held after the trade: 432,886 (-15.3%).